Pasithea Therapeutics Corp. Form 8-K Summary
Business context and reporting period
Pasithea Therapeutics Corp. filed a Form 8-K dated July 19, 2023, reporting a Nasdaq continued-listing matter under Item 3.01. The company is listed on the Nasdaq Capital Market under the symbols KTTA and KTTAW.
Key financial metrics
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics.
Material changes versus the prior comparable period
- On January 19, 2023, Nasdaq notified the company that its common stock had failed to meet the $1.00 minimum closing bid price requirement under Nasdaq Listing Rule 5550(a)(2) for 30 consecutive business days.
- The initial 180-day compliance period was scheduled to expire on July 18, 2023.
- On July 19, 2023, Nasdaq granted the company an additional 180-day extension, through January 15, 2024, to regain compliance.
Outlook, risks, contingencies, and unusual items
- The company will continue monitoring its common stock’s closing bid price.
- Management may consider available actions, including a reverse stock split, to regain compliance.
- If the company does not regain compliance by the extended deadline, Nasdaq may issue a delisting notice. The company would have the right to appeal that determination to a Nasdaq hearings panel.
- The filing states that there can be no assurance the company will regain compliance during the extension period.
Important facts for investors to verify
- Whether the common stock achieved a closing bid price of at least $1.00 for the period required by Nasdaq before January 15, 2024.
- Whether the company implemented a reverse stock split or another compliance measure.
- Whether Nasdaq issued a subsequent delisting notice or granted any further relief.
- The potential effects of any reverse stock split on shareholders, trading activity, and outstanding securities.